Oscotec Inc.

Translating science into medicine
회원가입
PRESS
  1. Yuhan ups investment in biotechs for immuno-oncology drug push

    Date2018-06-11 MediaTHE INVESTOR PipelineYuhan/Lazertinib
    Read More
  2. Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

    Date2016-01-19 MediaScrip (Informa Pharma Intelligence) PipelineSYK-O-703
    Read More
  3. G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

    Date2014-04-03 MediaPubMed PipelineSKI-G-801
    Read More
  4. Oscotec shares rebound on launch of US clinical trial

    Date2017-12-11 MediaKBR (; Korea Biomedical Review) PipelineSKI-G-801
    Read More
  5. Oscotec`s acute leukemia treatment wins orphan drug status from FDA

    Date2018-11-23 MediaKBR (; Korea Biomedical Review) PipelineSKI-G-801
    Read More
  6. Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

    Date2019-07-01 MediaCANCER RESEARCH PipelineSKI-G-801
    Read More
  7. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

    Date2019-11-04 MediaMolecular Cancer PipelineSKI-G-801
    Read More
  8. IPOs spawn instant billionaires

    Date2007-02-20 MediaThe Korea Herald PipelineOscotec
    Read More
  9. Profiles of Four New Stock-Billionaires

    Date2007-02-19 MediaMBN PipelineOscotec
    Read More
  10. INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

    Date2016-08-23 MediaScrip (Informa Pharma Intelligence) PipelineOscotec
    Read More
  11. Oscotec wins exception policy for continued R&D for new drugs

    Date2019-06-25 MediaKBR (; Korea Biomedical Review) PipelineOscotec
    Read More
  12. Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

    Date2021-03-02 MediaCISION PipelineOscotec
    Read More
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...